Bulletin
Investor Alert

New York Markets Open in:

Sept. 8, 2022, 4:32 p.m. EDT

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Edesa Biotech Inc. (EDSA)

or Cancel Already have a watchlist? Log In

Sep 08, 2022 (ACCESSWIRE via COMTEX) -- TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. /zigman2/quotes/200172674/composite EDSA +3.62% , a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference being held in New York, NY on September 12-14, 2022.

Edesa Presentation Details

Date: September 12, 2022
Time: 10:00 am Eastern Time
Presentation Slides: Available in the events section of the Edesa website .

Attendees who are interested in meeting with the company should contact their H.C. Wainwright representative or Edesa directly via email at investors@edesabiotech.com .

About Edesa Biotech, Inc.

Edesa Biotech, Inc. /zigman2/quotes/200172674/composite EDSA +3.62% is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that Edesa is developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. Sign up for news alerts . Connect with Edesa Biotech on Twitter and LinkedIn .

Contact

Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com

SOURCE: Edesa Biotech

COMTEX_414027639/2457/2022-09-08T16:31:47

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/200172674/composite
US : U.S.: Nasdaq
$ 0.92
+0.03 +3.62%
Volume: 106,105
Nov. 30, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$13.76 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/200172674/composite
US : U.S.: Nasdaq
$ 0.92
+0.03 +3.62%
Volume: 106,105
Nov. 30, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$13.76 million
Rev. per Employee
N/A
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.